It is a prime concern of Evotec that all relevant target groups receive the same information at the same time. This implies communicating in both English and German.

Please find below the most recent corporate news, ad hoc releases and other announcements of our Company.



Evotec AG announces first nine-month 2017 results and corporate update
Laura Catalina, 8 November 2017

Strong operational and financial performance Expansion of leading external innovation platform through acquisition of aptuit Important milestone achievements and new ways of accelerating innovation Hamburg, Germany, 08 November 2017: Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today reported financial results and...

Evotec joins forces with Academic Leaders to accelerate Drug Discovery in kidney diseases and build “Neplex”
Laura Catalina, 7 November 2017

Collaboration aimed at developing novel “Nephron-on-a Chip” device to test drug candidates in human kidney: NEPLEX (“Nephron-on-a-Chip with Cellular and Extracellular Matrix Complexity”) Major step forward to the next generation Kidney Platform Hamburg, Germany, 06 November 2017:Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN:...

Evotec AG to report first nine-month 2017 results on 08 November 2017
Laura Catalina, 2 November 2017

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) will report its financial results for the first nine months of 2017 on Wednesday, 08 November 2017. The Company is going to hold a conference call to discuss the results as well as to provide an update on its performance. The conference call will be held in English. ...


Other announcements


The following annoucement has been published in the German Federal Gazette in accordance with the German Conversion Act (Umwandlungsgesetz) in 2013. Pursuant to the German Conversion Act, certain transaction intended by Evotec AG, e.g. up-stream mergers, have to be announced in the Federal Gazette (Bundesanzeiger).

Contact us

Gabriele Hansen

VP, Corporate Communications & Investor Relations

T +49 40 560 81 255 F +49 40 560 81 333 vCard

Katja Werner

Investor Relations Associate

T +49 40 560 81 210 F +49 40 560 81 333 vCard